Trade Setup
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson’s disease cognitive impairment.
Stocks found in the category TradersPro New Uptrend are low priced stocks priced between .20 and $7, with at least 50k shares of average shares trading per day. The stocks are starting new uptrends and have buy signals. These are high reward to risk stocks with the potential for very sharp moves. A stop should be maintained at the low of the most recent hold signal day. Target prices for exits can be determined by using the next level of resistance higher or by using Fibonacci resistance levels found using TradersPro. Trailing stops or letting the stock run until the next sell signal is also a sell strategy.
